Ridgefield, Conn., January 16, 2018 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Gilotrif (afatinib) for the first-line treatment of patients…Original Article
FDA Approves New Indication for Gilotrif (afatinib) in EGFR Mutation-Positive NSCLC
